

9<sup>th</sup> February, 2019

To

BSE Limited  
Corporate Relationship Department  
P J Towers  
Dalal Street, Fort  
Mumbai – 400 001.

Dear Sir/Madam,

**Sub:** Outcome of Board Meeting held on 9<sup>th</sup> February, 2019

**Ref:** Security Code: 524520; Security ID; KMCSHIL

This is to inform you that the Board of Directors at their meeting held today, the 9<sup>th</sup> day of February, 2019 approved the Standalone Unaudited Financial results for the Quarter and 9 months period ended 31<sup>st</sup> December, 2018 along with the Limited Review Report of the Auditors, copy of which is enclosed for your records.

We hereby inform you that the Board Meeting commenced at 11.30 AM and concluded at 2.00. P.M.

Thank You

With regards,

For **KMC SPECIALITY HOSPITALS (INDIA) LIMITED**



**DR S MANIVANNAN**  
**MANAGING DIRECTOR**



**Regd. Office**

**KMC Speciality Hospitals (India) Ltd**

CIN - L85110TN1982PLC009781

No. 6, Royal Road, Cantonment, Trichy - 620 001.

T 0431-4077777 F 0431 - 2415402

E info@kauveryhospital.com W www.kauveryhospital.com



**KMC Speciality Hospitals (India) Limited**  
**Regd. Office: 6, Royal Road, Cantonment, Trichy - 620 001**  
**Corporate Identity Number: L85110TN1982PLC009781**

**Statement of unaudited financial results for the quarter and nine months period ended December 31, 2018**

	Particulars	Rs. In Lakhs					
		Quarter ended			Nine months period ended		Year ended
		December 31, 2018 (Unaudited)	September 30, 2018 (Unaudited)	December 31, 2017 (Unaudited)	December 31, 2018 (Unaudited)	December 31, 2017 (Unaudited)	March 31, 2018 (Audited)
<b>1</b>	<b>Income</b>						
	a) Revenue from operations	2,296.45	1,816.44	1,937.74	6,126.78	5,335.28	7,066.65
	b) Other income	21.19	18.27	11.42	57.15	21.00	32.16
	<b>Total income</b>	<b>2,317.64</b>	<b>1,834.71</b>	<b>1,949.16</b>	<b>6,183.93</b>	<b>5,356.28</b>	<b>7,098.81</b>
<b>2</b>	<b>Expenses</b>						
	a) Cost of materials consumed	52.74	38.55	43.86	132.21	130.23	171.48
	b) Purchase of traded goods	278.08	223.16	204.92	740.56	635.17	866.72
	c) Changes in inventory of traded goods	(8.15)	2.69	6.32	(5.48)	14.90	5.41
	d) Employee benefits expense	471.16	402.35	408.55	1,321.67	1,144.07	1,572.94
	e) Finance costs	26.40	28.04	16.83	86.79	47.95	78.70
	f) Depreciation and amortisation expense	101.73	107.07	108.37	314.35	285.58	386.38
	g) Other expenses	1,014.67	892.37	864.31	2,792.76	2,315.95	3,037.09
	<b>Total expenses</b>	<b>1,936.63</b>	<b>1,694.23</b>	<b>1,653.16</b>	<b>5,382.86</b>	<b>4,573.85</b>	<b>6,118.72</b>
<b>3</b>	<b>Profit before tax (1-2)</b>	<b>381.01</b>	<b>140.48</b>	<b>296.00</b>	<b>801.07</b>	<b>782.43</b>	<b>980.09</b>
<b>4</b>	<b>Income tax expense</b>						
	a) Current tax	101.18	34.34	77.30	215.01	183.82	226.43
	b) Deferred tax	(2.42)	9.08	17.00	8.15	83.01	88.48
	<b>Total income tax expense</b>	<b>98.76</b>	<b>43.42</b>	<b>94.30</b>	<b>223.16</b>	<b>266.83</b>	<b>314.91</b>
<b>5</b>	<b>Profit after tax (3-4)</b>	<b>282.25</b>	<b>97.06</b>	<b>201.70</b>	<b>577.91</b>	<b>515.60</b>	<b>665.18</b>
<b>6</b>	<b>Other comprehensive income</b>						
	Items that will not be reclassified subsequently to profit or loss						
	(a) Re-measurement of defined benefit plans	10.13	31.04	(4.92)	30.38	(20.12)	(43.15)
	(b) Income tax effect	(2.95)	(9.04)	1.70	(8.85)	6.96	14.93
	<b>Total other comprehensive income, net of tax</b>	<b>7.18</b>	<b>22.00</b>	<b>(3.22)</b>	<b>21.53</b>	<b>(13.16)</b>	<b>(28.22)</b>
<b>7</b>	<b>Total comprehensive income, net of tax (5+6)</b>	<b>289.43</b>	<b>119.06</b>	<b>198.48</b>	<b>599.44</b>	<b>502.44</b>	<b>636.96</b>
<b>8</b>	<b>Paid-up equity share capital (Face value of Re. 1/- each)</b>	<b>1,630.85</b>	<b>1,630.85</b>	<b>1,630.85</b>	<b>1,630.85</b>	<b>1,630.85</b>	<b>1,630.85</b>
<b>9</b>	<b>Reserves i.e. Other equity</b>						<b>1,409.91</b>
<b>10</b>	<b>Earnings per share (EPS) of Re. 1/- each :</b>						
	Basic and diluted EPS	0.17	0.06	0.12	0.35	0.32	0.41
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

**Notes:**

- The statement of unaudited financial results for the quarter and nine months period ended December 31, 2018, in respect of KMC Speciality Hospitals (India) Limited ("the Company") has been reviewed by Audit Committee and approved by the Board of Directors on February 9, 2019. The above results are subjected to limited review by the statutory auditors of the Company. The report of the statutory auditors is unqualified.
- These financial results have been prepared in accordance with Indian Accounting Standard ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016.
- Based on the "Management approach" as defined in Ind AS 108-Operating Segments, the Chief Operating Decision Maker evaluates the Company's performance as a single business segment namely "Medical and Healthcare services".
- Effective April 1, 2018, the Company has adopted Ind AS 115, "Revenue from contracts with customers". The application of Ind AS 115 did not have any material impact on the financial results of the Company.

Place: Chennai  
Date : February 9, 2019



**Dr. S. Manivannan**  
Managing Director  
DIN: 00910804

# B S R & Co. LLP

Chartered Accountants

Building No.10, 8th Floor, Tower-B  
DLF Cyber City, Phase - II  
Gurugram - 122 002, India

Telephone: + 91 124 719 1000  
Fax: + 91 124 235 8613

## Limited Review Report to The Board of Directors of KMC Speciality Hospitals (India) Limited

We have reviewed the accompanying statement of unaudited financial results of KMC Speciality Hospitals (India) Limited ('the Company') for the quarter ended December 31, 2018 and the year-to-date results for the period from April 1, 2018 to December 31, 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* specified under section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.: 101248W/W-100022



**S Sethuraman**

Partner

Membership No.: 203491

Place: Chennai

Date: February 9, 2019